

15 June 2009

## Proposal relating to cyclosporin A and clozapine

PHARMAC and Novartis New Zealand Limited have entered into a provisional agreement relating to the supply of Neoral (cyclosporin A 25 mg, 50 mg and 100 mg capsules and 100 mg per mL oral liquid) and Clozaril (clozapine 25 mg and 100 mg tablets). The key aspects of the proposal are as follows:

### *In relation to Neoral (cyclosporin A)*

- the Special Authority criteria applying to cyclosporin A would be removed from 1 September 2009, meaning that it would be subsidised when prescribed for indications other than those covered by the Special Authority;
- the prices and subsidies for Neoral would remain unchanged;
- from 1 September 2009 a rebate would apply to all Neoral community subsidies and hospital dispensings which would reduce the net effective price by up to 50%; and
- Neoral would have protection from subsidy reduction and delisting until 30 June 2010.

### *In relation to Clozaril (clozapine)*

- the prices and subsidies for Clozaril would remain unchanged;
- a 50% rebate would apply to all Clozaril community subsidies and hospital dispensings from 1 June 2009 onwards; and
- Clozaril would have protection from subsidy reduction and delisting until 30 June 2012.

### **Feedback sought**

We welcome your feedback on this proposal. To provide feedback please submit an email, fax or letter by **4 pm, Tuesday 30 June 2009** to:

Geraldine MacGibbon  
Therapeutic Group Manager  
PHARMAC  
PO Box 10-254  
Wellington 6143

Email: [geraldine.macgibbon@pharmac.govt.nz](mailto:geraldine.macgibbon@pharmac.govt.nz)  
Fax: (04) 460 4995

All feedback received before the closing date will be considered when a decision is made on this proposal by PHARMAC's Board (or Chief Executive under delegated authority).